retatrutide effects UK Guide: Key Facts on the New Weight-Loss Drug Lilly's retatrutide shows 28% weight

Most patients will gradually progress to multifocal functional or non-functional pancreatic neuroendocrine tumors

Novo Nordisk has nominated semaglutide for inclusion in the FDAs Demonstrable Difficulties for Compounding Lists

Foley E, Marsh C

Citations Citations to this article as recorded by Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches Prashant Tiwari, Istuti Saraswat, Jyoti Gupta Current Microbiology .2026;[Epub] CrossRef Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification Tai-Chung Tseng, Shang-Chin Huang, Jia-Horng Kao Hepatology Communications .2026;[Epub] CrossRef Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications Jiayan Yan, Jiayi Wang, Jian Fan, Xinyi Cui, Yuxi Zhang, Xinrong Yang, Qiang Gao, Zhenbin Ding, Zhaoyou Tang, Jia Fan, Dan G

People switching from other GLP-1 agonists Switching from semaglutide or tirzepatide to retatrutide is increasingly common as people seek greater weight loss results